Effect of recombinant human epidermal growth factor on cutaneous scar quality in thyroidectomy patients

J Dermatolog Treat. 2015 Apr;26(2):159-64. doi: 10.3109/09546634.2014.906034. Epub 2014 Apr 8.

Abstract

Background: Epidermal growth factor (EGF) decreases inflammatory cell infiltration and TGF-β expression during wound healing. Several clinical studies show that recovery of various ulcer wounds, such as diabetic and radiation ulcer, is promoted by EGF.

Objective: To evaluate effects of recombinant human epidermal growth factor (rhEGF) on cutaneous scar quality after thyroidectomy.

Method: Scar quality was evaluated by Vancouver scar scale (VSS) in two groups of female thyroidectomy patients (control, n = 11; rhEGF-treated, n = 10). Scar erythema, pigmentation, elasticity and hydration were measured by mexameter, cutometer and corneometer.

Results: Scar pliability (at 4 weeks) and thickness (2 weeks) after surgery were significantly lower in the rhEGF group than control. Total VSS score was significantly lower in the rhEGF group after 4 weeks. However, erythema, pigmentation, elasticity and hydration of the scar were not significantly different between groups.

Conclusion: The early use of rhEGF in surgical wound healing may improve cutaneous scar quality.

Keywords: Epidermal growth factor; prevention; scars.

Publication types

  • Clinical Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Cicatrix / drug therapy*
  • Epidermal Growth Factor / therapeutic use*
  • Erythema / epidemiology
  • Female
  • Humans
  • Male
  • Middle Aged
  • Prospective Studies
  • Recombinant Proteins
  • Thyroidectomy / adverse effects
  • Thyroidectomy / methods*
  • Wound Healing / drug effects*

Substances

  • Recombinant Proteins
  • Epidermal Growth Factor